Iovance Biotherapeutics targets significant market expansion, with lung cancer representing a $10B U.S. peak sales ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...
Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology ...
Twelve months later, Miller is healthy and preparing to host her family's holiday gathering. A regimen of biological drugs ...
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment. ...
A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...
Triple-negative breast cancer (TNBC) is an aggressive type of invasive breast cancer. TNBC differs from other types of invasive breast cancer in that it tends to grow and spread faster, has fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback